Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03609814 · ClinicalTrials.gov registry record

Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)

A clinical trial, sponsored by University of California, San Francisco.

Completed
Registry status
30
Enrollment target

NCT03609814 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03609814 has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
30 participants
Enrollment target

Study Summary

Fludarabine and clofarabine are chemotherapy drugs used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of clofarabine and fludarabine in their bodies and if drug levels are related to whether or not a child experiences severe side-effects during their bone marrow transplant. The hypothesis is that clinical and individual factors cause changes in clofarabine and fludarabine drug levels in pediatric bone marrow transplant patients and that high levels may cause severe side-effects.

Interventions

  • DRUG Fludarabine Injection
  • DRUG Clofarabine

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2016-01-26
Est. Completion 2020-06-30

What the Registry Record Tells You About NCT03609814

The ClinicalTrials.gov registry entry for NCT03609814 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Fludarabine Injection is the first listed.

NCT03609814 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03609814 about?

NCT03609814 is a clinical study titled "Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)". Fludarabine and clofarabine are chemotherapy drugs used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of clofarabine and fludarabine in their bodies and if drug levels are related to whether or not a...

What is the current status of trial NCT03609814?

This trial is currently completed. The enrollment target is 30 participants. The study started on 2016-01-26. Estimated completion is 2020-06-30.

What interventions are being tested in trial NCT03609814?

The interventions under investigation include: Fludarabine Injection (DRUG), Clofarabine (DRUG).

Who is sponsoring clinical trial NCT03609814?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.